Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 5Phase 3 3Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 23INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 4Cisplatin 3pembrolizumab 2fludarabine 2apatinib 2XELOX 2S 1 (combination) 2Paclitaxel 2Oxaliplatin 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Irinotecan 2Injections 2Gemcitabine 2Fulvestrant 2Epirubicin 2Drug Therapy 2Boron Neutron Capture Therapy 2titanium silicide 1tislelizumab 1surufatinib 1sintilimab 1pegfilgrastim 1nimotuzumab 1ipatasertib 1ferumoxides 1famitinib 1eribulin 1dalpiciclib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER_GOV × Surgical Procedures, Operative × Clear all
NCT06602063 2025-06-27

Surgery for Relapsed Ovarian Cancer in Precision

Shanghai Gynecologic Oncology Group

Phase 1/2 Not yet recruiting
33 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡